董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Briggs Morrison | 男 | Chair of the Board and Lead Independent Director | 67 | 33.75万美元 | 15.19 | 2026-02-12 |
| John Houston | -- | Director | 66 | 653.41万美元 | 256.44 | 2026-02-12 |
| Edward Kennedy, Jr. | 男 | Independent Director | 64 | 30.50万美元 | 15.01 | 2026-02-12 |
| Randy Teel | 男 | President, CEO and Director | 47 | 未披露 | 51.54 | 2026-02-12 |
| Linda C. Bain | -- | Independent Director | -- | 31.50万美元 | 7.36 | 2026-02-12 |
| Leslie V. Norwalk | -- | Independent Director | -- | 31.25万美元 | 8.74 | 2026-02-12 |
| Everett V. Cunningham | -- | Independent Director | -- | 31.25万美元 | 6.20 | 2026-02-12 |
| Sunil Agarwal | -- | Independent Director | -- | 31.50万美元 | 4.47 | 2026-02-12 |
| Laurie Smaldone Alsup | -- | Independent Director | -- | 31.00万美元 | 8.74 | 2026-02-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Randy Teel | 男 | President, CEO and Director | 47 | 未披露 | 51.54 | 2026-02-12 |
| David Loomis | -- | Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2026-02-12 |
| Andrew R. Saik | -- | Chief Financial Officer and Treasurer | -- | 336.23万美元 | 16.04 | 2026-02-12 |
| Noah Berkowitz | -- | Chief Medical Officer | -- | 359.40万美元 | 17.73 | 2026-02-12 |
| Angela Cacace | -- | Chief Scientific Officer | -- | 330.09万美元 | 37.58 | 2026-02-12 |
董事简历
中英对照 | 中文 | 英文- Briggs Morrison
-
Briggs Morrison，目前担任MPM资本的董事总经理，这是一家专注于医疗保健的风险投资公司，自2015年6月起任职。他曾在上市公司阿斯利康 PLC担任全球药物开发执行副总裁兼首席医疗官，于2012年1月至2015年6月期间领导公司的全球后期开发组织，并担任阿斯利康高级管理团队成员。此前，他曾于2007年至2012年1月在上市公司辉瑞公司担任过多个职位，最终被任命为辉瑞人类健康业务的医疗事务、安全和法规事务主管，还曾在默克制药公司的一个部门默沙东TERM2 Research Laboratories担任越来越多的职责，并于1995年至2007年升任肿瘤学临床科学副总裁，负责所有新型抗癌药物的临床开发。莫里森博士曾担任TransCelerate BioPharma Inc.的董事会主席，该公司是一家行业资助公司，负责改进临床试验的各个方面，2014年至2015年期间，他是FDA赞助的临床试验转化计划CTTI执行委员会的成员，并且是Arvinas、Oncorus和Repare Therapeutics的董事会成员，这三家公司都是一家上市公司，以及几家私营公司的董事会成员。此前，他曾担任Codiak Biosciences和NextCure Therapeutics的董事会成员。Morrison博士在乔治敦大学获得生物学学士学位，并在康涅狄格大学获得医学博士学位。
Briggs Morrison has served as a member of Werewolf Therapeutics, Inc. board of directors since November 2019. He has served as Executive Partner at MPM Capital since June 2015, and as the Chief Executive Officer and a member of the board of directors of Crossbow Therapeutics, Inc., a privately held biotechnology company, since February 2022. Previously, he served as President, Head of Research and Development, of Syndax Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from February 2022 to April 2023, and prior to that was the Chief Executive Officer of Syndax Pharmaceuticals, Inc., from June 2015 to January 2022. Dr. Morrison has served as a member of the board of directors of Arvinas Inc. since June 2018, and CRISPR Therapeutics AG since June 2025, each of which is a publicly traded biopharmaceutical company. Dr. Morrison previously served as a member of the board of directors of Syndax Pharmaceuticals, Inc., from July 2015 to May 2024, Carisma Therapeutics Inc. from July 2020 to October 2025, NextCure Inc. from March 2019 to April 2021, Codiak Biosciences Inc. from February 2018 to April 2021, Oncorus, Inc. from April 2016 to April 2021, and Repare Therapeutics Inc. from June 2017 to August 2024, each of which was a publicly traded biopharmaceutical company. He also serves as a member of the board of directors of several privately held biotechnology companies. Previously, Dr. Morrison was the Chief Medical Officer and Head of Global Medicines Development at AstraZeneca plc from January 2012 to June 2015. Before joining AstraZeneca, he held several positions at Pfizer Inc., including Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer's human health business. Dr. Morrison also previously held several positions at Merck Research Laboratories, a division of Merck & Co., Inc.,including Vice President, Clinical Sciences, Oncology. He was a member of the executive committee of the Clinical Trials Transformation Initiative sponsored by the FDA and is on the board of the Alliance for Clinical Research Excellence and Safety. Dr. Morrison has a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut Medical School. He completed residency training in internal medicine at Massachusetts General Hospital and a fellowship in medical oncology at the Dana Farber Cancer Institute. - Briggs Morrison，目前担任MPM资本的董事总经理，这是一家专注于医疗保健的风险投资公司，自2015年6月起任职。他曾在上市公司阿斯利康 PLC担任全球药物开发执行副总裁兼首席医疗官，于2012年1月至2015年6月期间领导公司的全球后期开发组织，并担任阿斯利康高级管理团队成员。此前，他曾于2007年至2012年1月在上市公司辉瑞公司担任过多个职位，最终被任命为辉瑞人类健康业务的医疗事务、安全和法规事务主管，还曾在默克制药公司的一个部门默沙东TERM2 Research Laboratories担任越来越多的职责，并于1995年至2007年升任肿瘤学临床科学副总裁，负责所有新型抗癌药物的临床开发。莫里森博士曾担任TransCelerate BioPharma Inc.的董事会主席，该公司是一家行业资助公司，负责改进临床试验的各个方面，2014年至2015年期间，他是FDA赞助的临床试验转化计划CTTI执行委员会的成员，并且是Arvinas、Oncorus和Repare Therapeutics的董事会成员，这三家公司都是一家上市公司，以及几家私营公司的董事会成员。此前，他曾担任Codiak Biosciences和NextCure Therapeutics的董事会成员。Morrison博士在乔治敦大学获得生物学学士学位，并在康涅狄格大学获得医学博士学位。
- Briggs Morrison has served as a member of Werewolf Therapeutics, Inc. board of directors since November 2019. He has served as Executive Partner at MPM Capital since June 2015, and as the Chief Executive Officer and a member of the board of directors of Crossbow Therapeutics, Inc., a privately held biotechnology company, since February 2022. Previously, he served as President, Head of Research and Development, of Syndax Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from February 2022 to April 2023, and prior to that was the Chief Executive Officer of Syndax Pharmaceuticals, Inc., from June 2015 to January 2022. Dr. Morrison has served as a member of the board of directors of Arvinas Inc. since June 2018, and CRISPR Therapeutics AG since June 2025, each of which is a publicly traded biopharmaceutical company. Dr. Morrison previously served as a member of the board of directors of Syndax Pharmaceuticals, Inc., from July 2015 to May 2024, Carisma Therapeutics Inc. from July 2020 to October 2025, NextCure Inc. from March 2019 to April 2021, Codiak Biosciences Inc. from February 2018 to April 2021, Oncorus, Inc. from April 2016 to April 2021, and Repare Therapeutics Inc. from June 2017 to August 2024, each of which was a publicly traded biopharmaceutical company. He also serves as a member of the board of directors of several privately held biotechnology companies. Previously, Dr. Morrison was the Chief Medical Officer and Head of Global Medicines Development at AstraZeneca plc from January 2012 to June 2015. Before joining AstraZeneca, he held several positions at Pfizer Inc., including Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer's human health business. Dr. Morrison also previously held several positions at Merck Research Laboratories, a division of Merck & Co., Inc.,including Vice President, Clinical Sciences, Oncology. He was a member of the executive committee of the Clinical Trials Transformation Initiative sponsored by the FDA and is on the board of the Alliance for Clinical Research Excellence and Safety. Dr. Morrison has a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut Medical School. He completed residency training in internal medicine at Massachusetts General Hospital and a fellowship in medical oncology at the Dana Farber Cancer Institute.
- John Houston
-
John Houston自2017年9月以来一直担任我们的董事会成员以及总裁兼首席执行官。休斯顿博士于2017年1月至2017年9月担任我们的研究与开发总裁兼首席科学官，并自2017年2月起担任我们的首席执行官。在加入Arvinas之前，休斯顿博士于2015年9月至2016年8月担任生物制药公司百时美施贵宝公司（Bristol Myers Squibb Company）的专业发现和研发地点演变高级副总裁，并于2010年10月至2015年9月担任高级副总裁疾病科学和生物制剂。Dr.Houston持有爱丁堡Heriot-Watt University微生物生物化学博士学位和B.SC.格拉斯哥大学医学微生物学学士学位。
John Houston has served as a member of Arvinas Holding Company, LLC board of directors and as Arvinas Holding Company, LLC President and Chief Executive Officer since September 2017. Dr. Houston served as Arvinas Holding Company, LLC President of Research and Development and Chief Scientific Officer from January 2017 to September 2017 and has functioned as Arvinas Holding Company, LLC principal executive officer since February 2017. Prior to joining Arvinas, Dr. Houston served as Senior Vice President of Specialty Discovery and R&D Site Evolution at Bristol Myers Squibb Company, a biopharmaceutical company, from September 2015 to August 2016 and as Senior Vice President Disease Sciences and Biologics from October 2010 to September 2015. Dr. Houston holds a Ph.D. in microbial biochemistry from Heriot-Watt University, Edinburgh and a B.Sc. in medical microbiology from the University of Glasgow. - John Houston自2017年9月以来一直担任我们的董事会成员以及总裁兼首席执行官。休斯顿博士于2017年1月至2017年9月担任我们的研究与开发总裁兼首席科学官，并自2017年2月起担任我们的首席执行官。在加入Arvinas之前，休斯顿博士于2015年9月至2016年8月担任生物制药公司百时美施贵宝公司（Bristol Myers Squibb Company）的专业发现和研发地点演变高级副总裁，并于2010年10月至2015年9月担任高级副总裁疾病科学和生物制剂。Dr.Houston持有爱丁堡Heriot-Watt University微生物生物化学博士学位和B.SC.格拉斯哥大学医学微生物学学士学位。
- John Houston has served as a member of Arvinas Holding Company, LLC board of directors and as Arvinas Holding Company, LLC President and Chief Executive Officer since September 2017. Dr. Houston served as Arvinas Holding Company, LLC President of Research and Development and Chief Scientific Officer from January 2017 to September 2017 and has functioned as Arvinas Holding Company, LLC principal executive officer since February 2017. Prior to joining Arvinas, Dr. Houston served as Senior Vice President of Specialty Discovery and R&D Site Evolution at Bristol Myers Squibb Company, a biopharmaceutical company, from September 2015 to August 2016 and as Senior Vice President Disease Sciences and Biologics from October 2010 to September 2015. Dr. Houston holds a Ph.D. in microbial biochemistry from Heriot-Watt University, Edinburgh and a B.Sc. in medical microbiology from the University of Glasgow.
- Edward Kennedy, Jr.
-
EdwardKennedy，Jr.是Epstein Becker Green梦百合和生命科学实践的合伙人，他自2014年以来一直在该公司实践。从2015年到2019年，肯尼迪先生担任康涅狄格州议会的州参议员，并于2017年当选为美国残疾人协会董事会主席。Kennedy先生目前在Arvinas，Inc.公司（一家生物制药公司）董事会任职。肯尼迪先生在卫斯理大学获得学士学位，在耶鲁大学获得环境研究硕士学位，在康涅狄格大学获得法学博士学位。
Edward Kennedy, Jr.,began serving on Innovage Holding Corp. Board in March 2021. Mr. Kennedy is a Partner at Epstein Becker Green in the healthcare and life science practice, where he has practiced since 2014. From 2015 to 2019, Mr. Kennedy served as a State Senator in the Connecticut General Assembly, and in 2017, he was elected Chair of the Board of the American Association of People with Disabilities. Mr. Kennedy currently serves on the board of directors of Arvinas, Inc. (Nasdaq: ARVN), a bio-pharmaceutical company. Mr. Kennedy earned a bachelor's degree from Wesleyan University, a Master's Degree in Environmental Studies from Yale University, and a Juris Doctor from the University of Connecticut. - EdwardKennedy，Jr.是Epstein Becker Green梦百合和生命科学实践的合伙人，他自2014年以来一直在该公司实践。从2015年到2019年，肯尼迪先生担任康涅狄格州议会的州参议员，并于2017年当选为美国残疾人协会董事会主席。Kennedy先生目前在Arvinas，Inc.公司（一家生物制药公司）董事会任职。肯尼迪先生在卫斯理大学获得学士学位，在耶鲁大学获得环境研究硕士学位，在康涅狄格大学获得法学博士学位。
- Edward Kennedy, Jr.,began serving on Innovage Holding Corp. Board in March 2021. Mr. Kennedy is a Partner at Epstein Becker Green in the healthcare and life science practice, where he has practiced since 2014. From 2015 to 2019, Mr. Kennedy served as a State Senator in the Connecticut General Assembly, and in 2017, he was elected Chair of the Board of the American Association of People with Disabilities. Mr. Kennedy currently serves on the board of directors of Arvinas, Inc. (Nasdaq: ARVN), a bio-pharmaceutical company. Mr. Kennedy earned a bachelor's degree from Wesleyan University, a Master's Degree in Environmental Studies from Yale University, and a Juris Doctor from the University of Connecticut.
- Randy Teel
-
Randy Teel于2018年加入Arvinas，拥有20年生物制药产业化经验。Teel博士自2024年4月起担任公司首席BINCE官，在该职位上负责公司战略、BINCE发展、企业传播和投资者关系。从2024年2月到2024年6月，Teel博士还担任公司的临时首席财务官、财务主管和首席财务官，同时公司进行了一项搜索，以确定公司的下一任永久首席财务官、财务主管和首席财务官。2021年9月至2024年4月，Teel博士担任公司高级副总裁，负责企业和BINCE发展。2018年5月至2021年9月，Teel博士担任公司企业发展副总裁。在加入Arvinas之前，2017年3月至2017年12月，Teel博士担任亚力兄制药的副总裁兼战略主管，负责长期规划，与研发和商业组织合作制定内联和生命周期管理战略；2015年3月至2017年3月，担任公司战略和企业风险管理执行董事。从2008年1月到2015年3月，Teel博士在全球管理咨询公司麦肯锡公司担任顾问，在那里他就商业、医疗和发展方面的问题为生物制药客户提供建议。Teel博士在冈扎加大学获得生物学学士学位，在耶鲁大学获得免疫生物学博士学位。
Randy Teel joined Arvinas in 2018 and has 20 years of biopharmaceutical industry experience. Dr. Teel has been the Company's Chief Biness Officer since April 2024, and in that role was responsible for corporate strategy, biness development, corporate communications, and investor relations. From February 2024 to June 2024, Dr. Teel also served as the Company's interim Chief Financial Officer, Treasurer and principal financial officer, while the Company undertook a search to identify the Company's next permanent Chief Financial Officer, Treasurer and principal financial officer. From September 2021 to April 2024, Dr. Teel served as the Company's Senior Vice President, Corporate and Biness Development. From May 2018 to September 2021, Dr. Teel served as the Company's Vice President of Corporate Development. Prior to Arvinas, from March 2017 to December 2017, Dr. Teel was Vice President and Head of Strategy at Alexion Pharmaceuticals, where he was responsible for long range planning, partnering with the R&D and commercial organizations as they developed inline and lifecycle management strategies, and from March 2015 to March 2017, he was Executive Director, Corporate Strategy and Enterprise Risk Management. From January 2008 to March 2015, Dr. Teel was a consultant at McKinsey & Company, a global management consulting firm, where he advised biopharmaceutical clients on issues in commercial, medical, and development. Dr. Teel received his B.Sc. in Biology at Gonzaga University and his Ph.D. in Immunobiology from Yale University. - Randy Teel于2018年加入Arvinas，拥有20年生物制药产业化经验。Teel博士自2024年4月起担任公司首席BINCE官，在该职位上负责公司战略、BINCE发展、企业传播和投资者关系。从2024年2月到2024年6月，Teel博士还担任公司的临时首席财务官、财务主管和首席财务官，同时公司进行了一项搜索，以确定公司的下一任永久首席财务官、财务主管和首席财务官。2021年9月至2024年4月，Teel博士担任公司高级副总裁，负责企业和BINCE发展。2018年5月至2021年9月，Teel博士担任公司企业发展副总裁。在加入Arvinas之前，2017年3月至2017年12月，Teel博士担任亚力兄制药的副总裁兼战略主管，负责长期规划，与研发和商业组织合作制定内联和生命周期管理战略；2015年3月至2017年3月，担任公司战略和企业风险管理执行董事。从2008年1月到2015年3月，Teel博士在全球管理咨询公司麦肯锡公司担任顾问，在那里他就商业、医疗和发展方面的问题为生物制药客户提供建议。Teel博士在冈扎加大学获得生物学学士学位，在耶鲁大学获得免疫生物学博士学位。
- Randy Teel joined Arvinas in 2018 and has 20 years of biopharmaceutical industry experience. Dr. Teel has been the Company's Chief Biness Officer since April 2024, and in that role was responsible for corporate strategy, biness development, corporate communications, and investor relations. From February 2024 to June 2024, Dr. Teel also served as the Company's interim Chief Financial Officer, Treasurer and principal financial officer, while the Company undertook a search to identify the Company's next permanent Chief Financial Officer, Treasurer and principal financial officer. From September 2021 to April 2024, Dr. Teel served as the Company's Senior Vice President, Corporate and Biness Development. From May 2018 to September 2021, Dr. Teel served as the Company's Vice President of Corporate Development. Prior to Arvinas, from March 2017 to December 2017, Dr. Teel was Vice President and Head of Strategy at Alexion Pharmaceuticals, where he was responsible for long range planning, partnering with the R&D and commercial organizations as they developed inline and lifecycle management strategies, and from March 2015 to March 2017, he was Executive Director, Corporate Strategy and Enterprise Risk Management. From January 2008 to March 2015, Dr. Teel was a consultant at McKinsey & Company, a global management consulting firm, where he advised biopharmaceutical clients on issues in commercial, medical, and development. Dr. Teel received his B.Sc. in Biology at Gonzaga University and his Ph.D. in Immunobiology from Yale University.
- Linda C. Bain
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Leslie V. Norwalk
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Everett V. Cunningham
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Sunil Agarwal
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Laurie Smaldone Alsup
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Randy Teel
Randy Teel于2018年加入Arvinas，拥有20年生物制药产业化经验。Teel博士自2024年4月起担任公司首席BINCE官，在该职位上负责公司战略、BINCE发展、企业传播和投资者关系。从2024年2月到2024年6月，Teel博士还担任公司的临时首席财务官、财务主管和首席财务官，同时公司进行了一项搜索，以确定公司的下一任永久首席财务官、财务主管和首席财务官。2021年9月至2024年4月，Teel博士担任公司高级副总裁，负责企业和BINCE发展。2018年5月至2021年9月，Teel博士担任公司企业发展副总裁。在加入Arvinas之前，2017年3月至2017年12月，Teel博士担任亚力兄制药的副总裁兼战略主管，负责长期规划，与研发和商业组织合作制定内联和生命周期管理战略；2015年3月至2017年3月，担任公司战略和企业风险管理执行董事。从2008年1月到2015年3月，Teel博士在全球管理咨询公司麦肯锡公司担任顾问，在那里他就商业、医疗和发展方面的问题为生物制药客户提供建议。Teel博士在冈扎加大学获得生物学学士学位，在耶鲁大学获得免疫生物学博士学位。
Randy Teel joined Arvinas in 2018 and has 20 years of biopharmaceutical industry experience. Dr. Teel has been the Company's Chief Biness Officer since April 2024, and in that role was responsible for corporate strategy, biness development, corporate communications, and investor relations. From February 2024 to June 2024, Dr. Teel also served as the Company's interim Chief Financial Officer, Treasurer and principal financial officer, while the Company undertook a search to identify the Company's next permanent Chief Financial Officer, Treasurer and principal financial officer. From September 2021 to April 2024, Dr. Teel served as the Company's Senior Vice President, Corporate and Biness Development. From May 2018 to September 2021, Dr. Teel served as the Company's Vice President of Corporate Development. Prior to Arvinas, from March 2017 to December 2017, Dr. Teel was Vice President and Head of Strategy at Alexion Pharmaceuticals, where he was responsible for long range planning, partnering with the R&D and commercial organizations as they developed inline and lifecycle management strategies, and from March 2015 to March 2017, he was Executive Director, Corporate Strategy and Enterprise Risk Management. From January 2008 to March 2015, Dr. Teel was a consultant at McKinsey & Company, a global management consulting firm, where he advised biopharmaceutical clients on issues in commercial, medical, and development. Dr. Teel received his B.Sc. in Biology at Gonzaga University and his Ph.D. in Immunobiology from Yale University.- Randy Teel于2018年加入Arvinas，拥有20年生物制药产业化经验。Teel博士自2024年4月起担任公司首席BINCE官，在该职位上负责公司战略、BINCE发展、企业传播和投资者关系。从2024年2月到2024年6月，Teel博士还担任公司的临时首席财务官、财务主管和首席财务官，同时公司进行了一项搜索，以确定公司的下一任永久首席财务官、财务主管和首席财务官。2021年9月至2024年4月，Teel博士担任公司高级副总裁，负责企业和BINCE发展。2018年5月至2021年9月，Teel博士担任公司企业发展副总裁。在加入Arvinas之前，2017年3月至2017年12月，Teel博士担任亚力兄制药的副总裁兼战略主管，负责长期规划，与研发和商业组织合作制定内联和生命周期管理战略；2015年3月至2017年3月，担任公司战略和企业风险管理执行董事。从2008年1月到2015年3月，Teel博士在全球管理咨询公司麦肯锡公司担任顾问，在那里他就商业、医疗和发展方面的问题为生物制药客户提供建议。Teel博士在冈扎加大学获得生物学学士学位，在耶鲁大学获得免疫生物学博士学位。
- Randy Teel joined Arvinas in 2018 and has 20 years of biopharmaceutical industry experience. Dr. Teel has been the Company's Chief Biness Officer since April 2024, and in that role was responsible for corporate strategy, biness development, corporate communications, and investor relations. From February 2024 to June 2024, Dr. Teel also served as the Company's interim Chief Financial Officer, Treasurer and principal financial officer, while the Company undertook a search to identify the Company's next permanent Chief Financial Officer, Treasurer and principal financial officer. From September 2021 to April 2024, Dr. Teel served as the Company's Senior Vice President, Corporate and Biness Development. From May 2018 to September 2021, Dr. Teel served as the Company's Vice President of Corporate Development. Prior to Arvinas, from March 2017 to December 2017, Dr. Teel was Vice President and Head of Strategy at Alexion Pharmaceuticals, where he was responsible for long range planning, partnering with the R&D and commercial organizations as they developed inline and lifecycle management strategies, and from March 2015 to March 2017, he was Executive Director, Corporate Strategy and Enterprise Risk Management. From January 2008 to March 2015, Dr. Teel was a consultant at McKinsey & Company, a global management consulting firm, where he advised biopharmaceutical clients on issues in commercial, medical, and development. Dr. Teel received his B.Sc. in Biology at Gonzaga University and his Ph.D. in Immunobiology from Yale University.
- David Loomis
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Andrew R. Saik
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Noah Berkowitz
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Angela Cacace
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介